LSBio Acquires Absolute Antibody Ltd.
LSBio (LSBio™), a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Redcar, UK-based Absolute Antibody, Ltd. and its sister company Kerafast. Terms of the transaction were not disclosed.
LSBio provides IHC-validated reagent antibodies and services to the global community of academic, pharmaceutical and biotech researchers. The Company has built a catalog of more than 750,000 reagent antibodies, assay kits, proteins, and biochemicals, and its acquisition of Absolute Antibody and Kerafast further expands its product portfolio by adding a range of unique reagents and antibody services.
Absolute Antibody specializes in recombinant antibody technology, offering antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies and Fc Fusion proteins, engineered into new and useful formats. In 2018, Absolute Antibody merged with Kerafast Inc., a Boston-based company that facilitates access to unique laboratory-made reagents, to further the availability of recombinant antibodies. The new acquisition combines a strong recombinant antibody portfolio with LSBio’s expertise in application-specific validation to make sequence-defined, reproducible antibodies more widely available for IHC and other key research applications.
“We are very excited to add Absolute Antibody and Kerafast into the LSBio family of companies,” said Dr. Heather Holemon, CEO of LSBio. “It provides an opportunity to offer more to our customers by adding their recombinant antibody production and engineering capabilities as well as their highly complementary product portfolio. This transaction aligns with our goal of providing researchers access to what they are asking for as far as superior consistency and better validation.”
“We are delighted to be joining forces with the LSBio team,” said Dr. Nicholas Hutchings, founder and CEO of Absolute Antibody. “Absolute Antibody was founded with a vision to make engineered recombinant antibodies accessible to all, and we have grown rapidly as the demand for recombinant antibody technology has increased. That vision remains and working with LSBio enables us to continue growing both the recombinant antibody catalog and our custom services, while still delivering the highest level of product quality and customer satisfaction.”
The acquisition marks the latest investment by LSBio to rapidly build its product portfolio. In 2019, LSBio acquired both Nordic-MUbio and Everest Biotech to strengthen the Company’s offering of proprietary monoclonal and polyclonal antibodies. All LSBio companies currently retain their independent names, websites and employees, with the entire family of companies owned by St. Louis-based private equity firm Thompson Street Capital Partners.
Absolute Antibody, Ltd. were advised by Pivotal Scientific Limited, a specialist Mergers and Acquisitions business based in Oxford, UK & Clark Holt, a specialist law firm based in Swindon UK.
About LSBio
LSBio (www.lsbio.com) enables researchers by providing a variety of antibodies and research reagents. Previous acquisitions of Nordic-MUbio and Everest Biotech have strengthened the company’s offering of proprietary monoclonal and polyclonal antibodies. The continued emphasis for LSBio has been on building the portfolio and coupling that with application-specific antibody validation. Through ongoing in-house testing, over 15,000 of the LSBio antibodies have been identified as exceptional IHC reagents and given the IHC-plus™ brand. LSBio itself was acquired by Thompson Street Capital Partners (TSCP) in 2018.
About Absolute Antibody
Absolute Antibody (www.absoluteantibody.com) was founded in 2012, with the vision to make engineered recombinant antibodies available to all. The company offers antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of engineered recombinant antibodies. Absolute Antibody customers include leading pharmaceutical, biotechnology and diagnostics companies, as well as academic researchers in more than 60 different countries worldwide.
About Kerafast
Kerafast, Inc. (www.kerafast.com) is a reagent company whose primary mission is to make unique laboratory-made research tools easily accessible to the global scientific community. Since its founding in 2011, Kerafast has partnered with more than 190 academic research institutions internationally and provided reagents to scientists in 63 countries across six continents. In 2018, Kerafast merged with Absolute Antibody, a company specializing in recombinant antibody technology, to further improve the selection of research tools available to the scientific community.
About TSCP
Thompson Street Capital Partners is a St. Louis-based private equity firm focused on investing in founder-led middle market businesses. TSCP has acquired more than 150 companies in the Healthcare & Life Science Services, Software & Technology Services and Business Services & Engineered Products sectors and have managed more than $2.6 billion since being founded in 2000. TSCP partners with management teams to increase value by accelerating growth, both organically and via complementary acquisitions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201222005100/en/
Contact information
Jeremy Milner
BackBay Communications
jeremy.milner@backbaycommunications.com
(401) 862-9422
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 05:00:00 EET | Press release
Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in real-time global treasury management. It has already supported a successful H
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo ™ 300mg18.11.2025 04:51:00 EET | Press release
The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These improvements may contribute to an enhanced treatment journey for patients by helping reduce the disease burden they face throughout their care. Given its distinctive product profile, Omlyclo™ 300mg has the potential to become an
2026 Mitsui Chemicals Catalysis Science Awards18.11.2025 04:00:00 EET | Press release
Mitsui Chemicals, Inc. has announced that online applications for the 2026 Mitsui Chemicals Catalysis Science Award have been open since September 1, 2025. The application period will run from September 1 to December 25, 2025. Aiming to contribute to the sustainable development of chemistry and the chemical industry, Mitsui Chemicals established the Mitsui Chemicals Catalysis Science Awards in 2004. The awards consist of the Catalysis Science Award and the Catalysis Science Award for Creative Work, which recognize outstanding achievements in the field of catalysis science. To date, the awards have been conferred on 33 researchers within Japan and overseas. Past recipients include individuals who have gone on to be highly acclaimed worldwide, receiving honors such as the Nobel Prize in Chemistry and other prestigious Japanese and international awards. We welcome applications from a wide range of R&D fields, including solid catalysts, molecular catalysts and biocatalysts, as well as gree
Access Advance Welcomes Xiaomi to HEVC Advance and VVC Advance Patent Pools as a Licensor and Licensee18.11.2025 03:00:00 EET | Press release
Access Advance LLC, an independent licensing administrator for leading video codec patent pools, today announced that Xiaomi has joined the HEVC Advance Patent Pool and the VVC Advance Patent Pool, as a Licensor and Licensee. "We are delighted to welcome Xiaomi to the Access Advance licensing community," said Peter Moller, CEO of Access Advance. "Xiaomi's participation in both our HEVC and VVC patent pools represents a significant milestone in the video codec licensing landscape. Their joining of the HEVC Advance Patent Pool, which provides them with access to tens of thousands of essential patents for the widely adopted H.265 standard, and their dual role as both a licensor and licensee in the VVC Advance Patent Pool, demonstrates their commitment to innovation and the recognition of the value of patent pools that balance the interest of patent owners and implementers. In addition, it highlights their support for Access Advance’s efforts to bring a one-pool solution to video codec lic
Venture Global Files FERC Application for Plaquemines Expansion Project18.11.2025 01:02:00 EET | Press release
Today, Venture Global, Inc. (NYSE: VG) filed with the Federal Energy Regulatory Commission (FERC) its application for the permitting and approval of the Plaquemines LNG brownfield expansion project. In addition, Venture Global has filed with the U.S. Department of Energy (DOE) for the export authorizations associated with this expansion. The Plaquemines Expansion was announced earlier this year with U.S. Secretary of Energy Chris Wright, U.S. Secretary of the Interior Doug Burgum, and Louisiana Governor Jeff Landry. Venture Global has since increased the expected output from this project by nearly 40% from the previously announced plans due to the continued optimization of our liquefaction trains and strong market demand. This bolt-on expansion will be built incrementally in three phases and consist of 32 modular liquefaction trains, adding in total over 30.0MTPA in peak production capacity. This will bring the total peak production capacity across the entire Plaquemines complex to ove
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom